“Retrospective Review Of Outcomes And Prognostic Factors Of Patients With COVID-19 Infection And Lymphoid Malignancy” Read more
An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma Read more
A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy Read more
A Phase 2 Study To Assess The Efficacy And Safety Of TGR-1202 (Umbralisib) Monotherapy In Patients With Non-Follicular Indolent Non-Hodgkin?S Lymphoma Read more
A Phase 2 Study To Assess The Efficacy And Safety Of Ublituximab And Umbralisib In Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib Or Venetoclax Read more
A Phase 1a/1b Dose Escalation And Expansion Trial Of TTI-621, A Novel Biologic Targeting CD47, In Subjects With Relapsed Or Refractory Hematologic Malignancies And Selected Solid Tumors Read more
A Phase 2, Multicenter, Single-Arm Study Of Zanubrutinib (BGB-3111) In Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant Of Prior Treatment With Ibrutinib Read more
A Phase 1b/2 Open-Label, Dose Escalation And Expansion Study Of Orally Administered Vrx-3996 And Valganciclovir In Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies Read more
